- Active not recruitingPHASE2
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy for children and young adults (3-25 years old) with newly diagnosed classical Hodgkin Lymphoma. It specifically focuses on those who aren't responding quickly to initial treatment.
For: Hodgkin LymphomaUnited States · Brazil · Colombia - Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia - RecruitingPHASE3
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study compares a new drug, odronextamab, with standard treatment for a type of lymphoma called DLBCL. It looks at how well they work with chemotherapy and their safety in adults who haven't been treated before, or whose lymphoma has come back.
For: Diffuse Large B-cell Lymphoma (DLBCL)United States · Australia · Austria - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
For: Hodgkin LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
This study is testing a new drug called odronextamab with chemotherapy for follicular lymphoma. It compares this new combination to the usual treatment (rituximab with chemotherapy) to see if it's safe, works well, and helps people with this type of cancer.
For: Follicular Lymphoma (FL)United States · Australia · Austria - RecruitingPHASE2
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
This study compares two treatments for a fast-growing blood cancer called diffuse large B-cell lymphoma (DLBCL), specifically a type called GCB DLBCL. Researchers want to see if a new drug, zilovertamab vedotin, when combined with standard therapy, works better than another combination in shrinking the cancer.
For: Lymphoma, Large B-Cell, DiffuseUnited States · Belgium · Germany - RecruitingPHASE1, PHASE2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
This study is testing a new drug, surovatamig, for different types of B-cell blood cancers like leukaemia and lymphoma. Researchers want to see if it's safe and effective, either alone or with other cancer treatments.
For: Chronic Lymphocytic Leukaemia · Small Lymphocytic Lymphoma · Mantle-cell LymphomaUnited States · Australia · China - RecruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
For: Follicular Lymphoma (FL)United States · Australia · Belgium - Active not recruitingPHASE3
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.
For: Relapsed/Refractory Follicular LymphomaUnited States · France · Germany - Active not recruitingPHASE3
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
This study compares a new drug combination (Lurbinectedin and Doxorubicin) against Doxorubicin alone for people with advanced leiomyosarcoma, a rare type of cancer. It aims to see if the combination can keep the cancer from growing for longer.
For: LeiomyosarcomaUnited States · Austria · Belgium - Active not recruitingPHASE2
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
This study is looking into a new treatment for an aggressive type of breast cancer called triple-negative breast cancer. It combines standard chemotherapy with two newer drugs, Atezolizumab and Ipatasertib, to see if this mix can fight the cancer better before surgery.
For: Triple Negative Breast CancerUnited Kingdom - RecruitingPHASE2
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
The REFRACT trial explores new treatments for follicular lymphoma that has come back or not responded to previous therapy. It compares new drugs with standard care to see if they offer better results for patients.
For: Relapsed Follicular Lymphoma · Refractory Follicular LymphomaUnited Kingdom - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
This study looks at a new drug, golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or not responded to previous treatments. It compares this new combination to standard treatments chosen by doctors.
For: Follicular LymphomaUnited States · Australia · Brazil - Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
This study looks at a new drug, golcadomide, combined with standard treatment for follicular lymphoma that's been recently diagnosed and is advanced. We want to see how well this new combination works and if it's safe for patients.
For: Lymphoma, FollicularUnited States · Australia · Brazil - RecruitingPHASE3
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
This study compares a new drug, Puxitatug Samrotecan, with standard chemotherapy for advanced endometrial cancer that has returned after previous treatments. It aims to see if the new drug can help patients live longer or stop their cancer from getting worse.
For: Endometrial Cancer · Malignant Solid TumourUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
This study is looking into a new drug, epcoritamab, for people with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares epcoritamab combined with standard treatment (R-CHOP) to R-CHOP alone, to see if the new combination works better.
For: Diffuse Large B-Cell LymphomaUnited States · Australia · Austria - Active not recruitingPHASE3
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
This study looks at a new drug, sacituzumab govitecan, for women with endometrial cancer that has come back or hasn't responded to earlier treatments. It compares this new drug to standard treatments chosen by doctors, aiming to see if it helps women live longer or keeps cancer from growing.
For: Endometrial CancerUnited States · Australia · Brazil - RecruitingPHASE2
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
This study is testing a new drug, acalabrutinib, alongside the usual treatment (CHOP-R) for Richter's Syndrome. It aims to see if this combination improves outcomes for people recently diagnosed with this aggressive blood cancer.
For: Richter SyndromeUnited Kingdom - RecruitingPHASE3
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
This study looks at new ways to treat a serious childhood cancer called neuroblastoma. It tests different treatment combinations, including chemotherapy and immunotherapy, to find the best approach for children with high-risk forms of the disease. The aim is to improve their chances of getting better.
For: NeuroblastomaAustralia · Austria · Belgium - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
For: Breast Neoplasms · Triple Negative Breast Neoplasms · HR Low-Positive/HER2-Negative Breast NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
This study is looking at a new treatment (BNT323) for women with advanced womb cancer that has come back. It compares BNT323 to standard chemotherapy to see if it works better at shrinking tumours and keeping the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
This study is testing a new drug, odronextamab, for adults with follicular lymphoma that hasn't been treated before. It aims to find out if the drug is safe and how well it works compared to current standard treatments.
For: Follicular Lymphoma (FL)United States · Australia · Austria - Active not recruitingPHASE3
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
This study compares a new medicine, sacituzumab tirumotecan, with standard chemotherapy for endometrial cancer. It's for people whose cancer has returned or progressed after previous treatments (platinum-based chemotherapy and immunotherapy). Researchers want to see if the new medicine helps people live longer and keeps the cancer from getting worse.
For: Endometrial CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
This study looks at new ways to treat childhood acute lymphoblastic leukemia (ALL). It explores how to choose the right treatment strength for each child and tests a new way to give a common chemotherapy drug called pegaspargase.
For: Acute Lymphoblastic Leukemia, PediatricUnited States · Canada - RecruitingPHASE3
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
This study looks at new ways to treat childhood leukaemia (ALL) in children and teenagers. It aims to make treatments kinder and more effective by using smart medicines (immunotherapy) and targeting specific cancer features, reducing the need for harsh chemotherapy.
For: Acute Lymphoblastic Leukemia, PediatricAustralia · Austria · Czechia - RecruitingPHASE3
Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas
This study looks at whether extra chemotherapy before surgery can help people with a certain type of soft-tissue sarcoma. It compares the standard 3 cycles of chemo with 6 cycles to see if it stops the cancer coming back or spreading.
For: Non-metastatic Soft-tissue Sarcoma · ResectableFrance - RecruitingPHASE3
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
This study is testing a new combination of drugs, mosunetuzumab and lenalidomide, for follicular lymphoma. It compares this new treatment to standard chemotherapy for people who haven't had treatment before. The aim is to see if the new combination works better and is safe.
For: Follicular LymphomaAustria · Belgium · France - Active not recruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This study looks at a new drug, Glofitamab, combined with standard treatment for a type of lymphoma called DLBCL. It aims to see if this new combination is safe and effective for patients who haven't been treated before and have a high-risk form of the disease.
For: LymphomaUnited States · Denmark · France - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - RecruitingPHASE3
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
This study looks at new ways to treat a type of cancer in children and teenagers called lymphoblastic lymphoma. It compares different medications and treatment approaches to find the most effective and safest options for patients in the UK and other countries.
For: Lymphoblastic Lymphoma, ChildhoodAustria · Belgium · China - RecruitingPHASE2
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
This study looks at new treatments (Dostarlimab alone or with Bevacizumab) for certain gynaecological cancers that have come back or not responded to previous treatment, comparing them to standard chemotherapy. It aims to see which treatment works best.
For: Ovarian Neoplasms · Endometrial Neoplasms · Uterine Cervical NeoplasmsAustralia · Hong Kong · Japan - Active not recruitingPHASE3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
This study compares a new treatment, axicabtagene ciloleucel, with standard care for adults recently diagnosed with high-risk large B-cell lymphoma. It aims to see if the new treatment works better as a first treatment option.
For: High-risk Large B-cell Lymphoma (LBCL)United States · Australia · Austria - Active not recruitingPHASE1, PHASE2
A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)
This study looks at a new drug, Nivolumab, combined with standard treatment (ABVD) for Hodgkin lymphoma. The goal is to improve the chances of a cure, especially for people with higher-risk forms of the disease. It checks if adding Nivolumab helps when initial treatment doesn't fully clear the cancer.
For: Hodgkin LymphomaUnited States · Canada - Active not recruitingPHASE3
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
This study is looking at a new treatment called glofitamab for a type of cancer called large B-cell lymphoma. It compares this new treatment, along with other medicines, against a standard treatment for people who haven't had treatment before.
For: Large B-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
This study, called NIAGARA-2, is looking at a new way to treat bladder cancer that has grown into the muscle. It combines a drug called durvalumab with standard chemotherapy, given before and after surgery. The aim is to see if this combination improves treatment.
For: Urinary Bladder Neoplasms · Immune Checkpoint Inhibitors · MethotrexateAustralia · Brazil · Canada - Active not recruitingPHASE3
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
This study looks at a new drug called acalabrutinib combined with standard chemotherapy (R-CHOP) for a type of blood cancer called Diffuse Large B-Cell Lymphoma, in people who haven't had treatment before. We want to see if this combination works better and is safe.
For: Diffuse Large B-Cell LymphomaUnited States · Australia · Austria - RecruitingPHASE3
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
This study looks at the best way to treat a rare childhood lung cancer called Pleuropulmonary Blastoma (PPB). For Type I PPB, it compares surgery alone to surgery with chemotherapy. For Types II and III PPB, it adds a new drug, Topotecan, to standard treatment.
For: Pleuropulmonary BlastomaUnited States · Canada - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
For: RhabdomyosarcomaAustralia · Austria · Belgium - Active not recruitingPHASE3
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
This study looks at a new drug, Golcadomide, combined with standard chemotherapy (R-CHOP) for a type of blood cancer called large B-cell lymphoma. It wants to see if this new combination is safer and works better than R-CHOP alone for patients who haven't been treated before and have a high-risk form of the disease.
For: Large B-cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
This study looks at a new drug, zilovertamab vedotin, combined with standard treatment for a type of blood cancer called diffuse large B-cell lymphoma (DLBCL). Researchers want to see if this new combination helps people live longer without their cancer growing or spreading, compared to standard treatment alone.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - RecruitingPHASE3
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
This study looks at combining immunotherapy (pembrolizumab) with chemotherapy (doxorubicin) for certain aggressive sarcomas. It compares this combination to chemotherapy alone, hoping to find a better way to stop the cancer from growing and spreading.
For: Metastatic Dedifferentiated Liposarcoma · Metastatic Undifferentiated Pleomorphic Sarcoma · Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8United States · Canada · Puerto Rico - Not yet recruitingPHASE2
The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
This study looks at a new way to treat high-risk stomach cancer after surgery. It combines standard chemotherapy with a special treatment called PIPAC, where chemotherapy drugs are sprayed directly inside the tummy, to see if it can stop the cancer from coming back.
For: Gastric Cancer · Chemotherapy, Adjuvant · Peritoneal MetastasesUnited States · Denmark · France - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - RecruitingPHASE1
In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma
This study explores a new way to treat sarcoma that has spread to the lungs. It involves delivering chemotherapy directly into one lung during surgery to kill cancer cells, aiming to reduce side effects and improve outcomes compared to standard treatments.
For: Bone Sarcoma · Soft Tissue Sarcoma · Pulmonary MetastasesCanada - Active not recruitingPHASE1, PHASE2
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
This study is testing a new drug, E7386, alongside other cancer medicines. It aims to find the safest and most effective dose for people with various solid tumours, especially endometrial cancer, and to understand how these combinations work.
For: Endometrial Neoplasms · Neoplasms · Carcinoma, HepatocellularUnited States · Canada · China - Active not recruitingPHASE3
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
This study is looking at a new treatment combination for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL). It combines a new drug, tafasitamab, and another drug, lenalidomide, with standard chemotherapy to see if it works better than chemotherapy alone.
For: Diffuse Large B-cell LymphomaUnited States · Argentina · Australia